Lorlatinib: a new-generation drug for ALK-positive NSCLC

Waqar Saiama N.; Morgensztern Daniel

首页> 外文期刊>The lancet oncology >Lorlatinib: a new-generation drug for ALK-positive NSCLC

【24h】

Lorlatinib: a new-generation drug for ALK-positive NSCLC

机译：Lorlatinib：ALK阳性NSCLC的新一代药物

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The lancet oncology》 |2018年第12期|共4页
作者
Waqar Saiama N.; Morgensztern Daniel;
展开▼
作者单位

Washington Univ Sch Med Div Med Oncol St Louis MO 63110 USA;

Washington Univ Sch Med Div Med Oncol St Louis MO 63110 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Lorlatinib: a new-generation drug for ALK-positive NSCLC [J] . Waqar Saiama N., Morgensztern Daniel The lancet oncology . 2018,第12期

机译：Lorlatinib：ALK阳性NSCLC的新一代药物
2. MA26.01 Accumulation of Concomitant Mutations Involved in Drug Resistance in the Sequential ALK TKI Treatments of ALK-Positive NSCLC [J] . S. Lu, Y. Yu, Y. Ding, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第10期

机译：MA26.01在ALK阳性NMSCLC的顺序ALK TKI治疗中累积涉及耐药性抗药性的致力突变
3. Drug Design for ALK-Positive NSCLC: an Integrated Pharmacophore-Based 3D QSAR and Virtual Screening Strategy [J] . James Nivya, Shanthi V., Ramanathan K. Applied biochemistry and biotechnology, Part A. enzyme engineering and biotechnology . 2018,第1期

机译：ALK阳性NSCLC的药物设计：基于综合的药镜3D QSAR和虚拟筛选策略
4. Delta-Radiomics Signature For Prediction Of Survival In Advanced Nsclc Patients Treated With Immunotherapy [C] . B. Farina, A. D. Ramos Guerra, C. Palacios Miras, IEEE International Symposium on Biomedical Imaging . 2021

机译：用于预测免疫疗法治疗的高级NSCLC患者存活的三角洲 - 辐射瘤
5. Exploitation and mechanistic validation of drug-combination strategies to overcome EGFR-inhibitor resistance in NSCLC cells [D] . Wang, Yu-Chieh. 2008

机译：克服NSCLC细胞中EGFR抑制剂耐药性的药物联合策略的开发和机理验证
6. Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report [O] . Go Makimoto, Keita Kawakado, Masamoto Nakanishi, 2021

机译：在邻吲哚菌诱导的肝脏损伤的肺阳性非小细胞肺癌中造成后的成功治疗：案例报告
7. An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC [O] . Viola W. Zhu, Yen-Ting Lin, Dong-Wan Kim, 2020

机译：对酪氨酸激酶抑制剂 - 难治性ALK阳性或ROS1阳性NMSCLC患者的早期或扩展途径通过早期或扩展的接入程序的国际实际研究综合分析

Lorlatinib: a new-generation drug for ALK-positive NSCLC

著录项

相似文献

相关主题

期刊订阅